Promoter hypermethylation of the CFTR gene and clinical/pathological features associated with non-small cell lung cancer

Respirology

Volumn 16, Issue 8, 2011, Pages 1203-1209

  Son, Ji Woong ^a   Kim, Young Jin ^b   Cho, Hyun Min ^b   Lee, Soo Young ^c   Lee, Su Man ^e   Kang, Jae Ku ^b   Lee, Jung Uee ^d   Lee, Yu Mi ^a   Kwon, Sun Jung ^a   Choi, Eugene ^a   Na, Moon Jun ^a   Park, Jae Yong ^f   Kim, Dong Sun ^e  

^a Departments of Internal Medicine   (South Korea)

^b Konyang University   (South Korea)

^c Myunggok Research Institute for Medical Science   (South Korea)

^d Daejeon St Mary's Hospital   (South Korea)

^e Kyungpook National University School of Medicine   (South Korea)

^f Kyungpook National University Hospital   (South Korea)

Author keywords

CFTR gene; DNA methylation; non small cell lung cancer; prognosis

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENE ACTIVATION; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC CORRELATION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PYROSEQUENCING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DNA METHYLATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; REPUBLIC OF KOREA;

EID: 80155180535     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2011.01994.x     Document Type: Article

References (35)

1. Baylin SB, Herman JG,. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 2000; 16: 168-74. (Pubitemid 30169152)
2. Jones PA, Baylin SB,. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 2002; 3: 415-28. (Pubitemid 34587077)
3. Belinsky SA,. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat. Rev. Cancer 2004; 4: 707-17. (Pubitemid 39215069)
4. Tsou JA, Hagen JA, Carpenter CL, et al,. DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene 2002; 21: 5450-61. (Pubitemid 34983481)
5. Yanagawa N, Tamura G, Oizumi H, et al,. Promoter hypermethylation of tumor suppressor and tumor-related genes in non-small cell lung cancers. Cancer Sci. 2003; 94: 589-92. (Pubitemid 36975012)
6. Alberg AJ, Brock MV, Samet JM,. Epidemiology of lung cancer: looking to the future. J. Clin. Oncol. 2005; 23: 3175-85. (Pubitemid 46217457)
7. Sheppard DN, Welsh MJ,. Structure and function of the CFTR chloride channel. Physiol. Rev. 1999; 79: 23-45.
8. Schwiebert EM, Benos DJ, Egan ME, et al,. CFTR is a conductance regulator as well as a chloride channel. Physiol. Rev. 1999; 79: 145-66.
9. van der Deen M, de Vries EG, Timens W, et al,. ATP-binding cassette (ABC) transporters in normal and pathological lung. Respir. Res. 2005; 6: 59.
10. Li C, Naren AP,. Macromolecular complexes of cystic fibrosis transmembrane conductance regulator and its interacting partners. Pharmacol. Ther. 2005; 108: 208-23. (Pubitemid 41527085)
11. Li Y, Sun Z, Wu Y, et al,. Cystic fibrosis transmembrane conductance regulator gene mutation and lung cancer risk. Lung Cancer 2010; 70: 14-21.
12. Neglia JP, FitzSimmons SC, Maisonneuve P, et al,. The risk of cancer among patients with cystic fibrosis. Cystic Fibrosis and Cancer Study Group. N. Engl. J. Med. 1995; 332: 494-9.
13. Padua RA, Warren N, Grimshaw D, et al,. The cystic fibrosis delta F508 gene mutation and cancer. Hum. Mutat. 1997; 10: 45-8. (Pubitemid 27298948)
14. Jacquot J, Tabary O, Le Rouzic P, et al,. Airway epithelial cell inflammatory signalling in cystic fibrosis. Int. J. Biochem. Cell Biol. 2008; 40: 1703-15.
15. Yu J, Zhu T, Wang Z, et al,. A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer. Clin. Cancer Res. 2007; 13: 7296-304.
16. Moribe T, Iizuka N, Miura T, et al,. Methylation of multiple genes as molecular markers for diagnosis of a small, well-differentiated hepatocellular carcinoma. Int. J. Cancer 2009; 125: 388-97.
17. Ding S, Gong BD, Yu J, et al,. Methylation profile of the promoter CpG islands of 14 'drug-resistance' genes in hepatocellular carcinoma. World J. Gastroenterol. 2004; 10: 3433-40. (Pubitemid 39549543)
18. Singh AP, Moniaux N, Chauhan SC, et al,. Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. Cancer Res. 2004; 64: 622-30. (Pubitemid 38120902)
19. Singh AP, Chauhan SC, Andrianifahanana M, et al,. MUC4 expression is regulated by cystic fibrosis transmembrane conductance regulator in pancreatic adenocarcinoma cells via transcriptional and post-translational mechanisms. Oncogene 2007; 26: 30-41. (Pubitemid 46067329)
20. Maiuri L, Luciani A, Giardino I, et al,. Tissue transglutaminase activation modulates inflammation in cystic fibrosis via PPARgamma down-regulation. J. Immunol. 2008; 180: 7697-705.
21. Bartoszewski R, Rab A, Twitty G, et al,. The mechanism of cystic fibrosis transmembrane conductance regulator transcriptional repression during the unfolded protein response. J. Biol. Chem. 2008; 283: 12154-65.
22. Toyooka S, Maruyama R, Toyooka KO, et al,. Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int. J. Cancer 2003; 103: 153-60. (Pubitemid 35461506)
23. Wistuba II, Behrens C, Milchgrub S, et al,. Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene 1999; 18: 643-50. (Pubitemid 29080321)
24. Fujita T, Kiyama M, Tomizawa Y, et al,. Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes. Int. J. Oncol. 1999; 15: 927-34.
25. Mills NE, Fishman CL, Rom WN, et al,. Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma. Cancer Res. 1995; 55: 1444-7.
26. Lai JC, Cheng YW, Goan YG, et al,. Promoter methylation of O(6)-methylguanine-DNA-methyltransferase in lung cancer is regulated by p53. DNA Repair (Amst.) 2008; 7: 1352-63.
27. Cantin AM, Hanrahan JW, Bilodeau G, et al,. Cystic fibrosis transmembrane conductance regulator function is suppressed in cigarette smokers. Am. J. Respir. Crit. Care Med. 2006; 173: 1139-44. (Pubitemid 43726895)
28. Martini N, Bains MS, Burt ME, et al,. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J. Thorac. Cardiovasc. Surg. 1995; 109: 120-9.
29. Mountain CF,. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111: 1710-17. (Pubitemid 27260107)
30. Goldstraw P, Crowley J, Chansky K, et al,. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J. Thorac. Oncol. 2007; 2: 706-14. (Pubitemid 47357522)
31. Brock MV, Hooker CM, Ota-Machida E, et al,. DNA methylation markers and early recurrence in stage I lung cancer. N. Engl. J. Med. 2008; 358: 1118-28. (Pubitemid 351398486)
32. Seng TJ, Currey N, Cooper WA, et al,. DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma. Br. J. Cancer 2008; 99: 375-82.
33. Suzuki M, Mohamed S, Nakajima T, et al,. Aberrant methylation of CXCL12 in non-small cell lung cancer is associated with an unfavorable prognosis. Int. J. Oncol. 2008; 33: 113-19.
34. Suzuki M, Yoshino I,. Aberrant methylation in non-small cell lung cancer. Surg. Today 2010; 40: 602-7.
35. Hsu HS, Wen CK, Tang YA, et al,. Promoter hypermethylation is the predominant mechanism in hMLH1 and hMSH2 deregulation and is a poor prognostic factor in nonsmoking lung cancer. Clin. Cancer Res. 2005; 11: 5410-16.